Home / Journals / OR / Vol.32, No.7, 2024
Special Issues
Table of Content
  • Open AccessOpen Access

    REVIEW

    Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment

    PAULINA CHMIEL1,2, ALEKSANDRA SłOWIKOWSKA1,2, ŁUKASZ BANASZEK1,2, ANNA SZUMERA-CIEćKIEWICZ3, BARTłOMIEJ SZOSTAKOWSKI1, MATEUSZ J. SPAłEK1,4,*, TOMASZ ŚWITAJ1, PIOTR RUTKOWSKI1, ANNA M. CZARNECKA1
    Oncology Research, Vol.32, No.7, pp. 1141-1162, 2024, DOI:10.32604/or.2024.050350 - 20 June 2024
    (This article belongs to the Special Issue: Novel Targets and Biomarkers in Solid Tumors)
    Abstract Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult… More >

  • Open AccessOpen Access

    ARTICLE

    Exploring the effects of taurolidine on tumor weight and microvessel density in a murine model of osteosarcoma

    LISANNE K.A. NEIJENHUIS1,2,3,#, LEUTA L. NAUMANN4,#, SONIA A.M. FERKEL1, SAMUEL J.S. RUBIN1, STEPHAN ROGALLA1,*
    Oncology Research, Vol.32, No.7, pp. 1163-1172, 2024, DOI:10.32604/or.2024.050907 - 20 June 2024
    Abstract Background: Osteosarcoma is the most common malignant primary bone tumor. The prognosis for patients with disseminated disease remains very poor despite recent advancements in chemotherapy. Moreover, current treatment regimens bear a significant risk of serious side effects. Thus, there is an unmet clinical need for effective therapies with improved safety profiles. Taurolidine is an antibacterial agent that has been shown to induce cell death in different types of cancer cell lines. Methods: In this study, we examined both the antineoplastic and antiangiogenic effects of taurolidine in animal models of osteosarcoma. K7M2 murine osteosarcoma cells were… More >

  • Open AccessOpen Access

    ARTICLE

    IKIP downregulates THBS1/FAK signaling to suppress migration and invasion by glioblastoma cells

    ZHAOYING ZHU1,#, YANJIA HU2,#, FENG YE2, HAIBO TENG2, GUOLIANG YOU1, YUNHUI ZENG2, MENG TIAN2, JIANGUO XU2, JIN LI2, ZHIYONG LIU2, HAO LIU2,*, NIANDONG ZHENG1,*
    Oncology Research, Vol.32, No.7, pp. 1173-1184, 2024, DOI:10.32604/or.2024.042456 - 20 June 2024
    Abstract Background: Inhibitor of NF-κB kinase-interacting protein (IKIP) is known to promote proliferation of glioblastoma (GBM) cells, but how it affects migration and invasion by those cells is unclear. Methods: We compared levels of IKIP between glioma tissues and normal brain tissue in clinical samples and public databases. We examined the effects of IKIP overexpression and knockdown on the migration and invasion of GBM using transwell and wound healing assays, and we compared the transcriptomes under these different conditions to identify the molecular mechanisms involved. Results: Based on data from our clinical samples and from public databases, More >

  • Open AccessOpen Access

    ARTICLE

    Silencing of the long non-coding RNA LINC00265 triggers autophagy and apoptosis in lung cancer by reducing protein stability of SIN3A oncogene

    XIAOBI HUANG1,#, CHUNYUAN CHEN2, YONGYANG CHEN1,#, HONGLIAN ZHOU1, YONGHUA CHEN1, ZHONG HUANG1, YULIU XIE1, BAIYANG LIU1, YUDONG GUO1, ZHIXIONG YANG1, GUANGHUA CHEN3,*, WENMEI SU1,4,*
    Oncology Research, Vol.32, No.7, pp. 1185-1195, 2024, DOI:10.32604/or.2023.030771 - 20 June 2024
    Abstract Background: Long non-coding RNAs are important regulators in cancer biology and function either as tumor suppressors or as oncogenes. Their dysregulation has been closely associated with tumorigenesis. LINC00265 is upregulated in lung adenocarcinoma and is a prognostic biomarker of this cancer. However, the mechanism underlying its function in cancer progression remains poorly understood. Methods: Here, the regulatory role of LINC00265 in lung adenocarcinoma was examined using lung cancer cell lines, clinical samples, and xenografts. Results: We found that high levels of LINC00265 expression were associated with shorter overall survival rate of patients, whereas knockdown of LINC00265 inhibited proliferation… More >

  • Open AccessOpen Access

    ARTICLE

    Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition

    ANGUO WU1,#, JIAO YAN2,3,#, TING SU2,4, CHI FENG1, XIN LONG5,6, YIRU PAN1, RUPEI YE2, TIAN XIA2, HANAN LONG2, JIANMING WU1,*, XIULI XIAO2,*
    Oncology Research, Vol.32, No.7, pp. 1197-1207, 2024, DOI:10.32604/or.2024.046139 - 20 June 2024
    (This article belongs to the Special Issue: Signaling Pathway Crosstalk in Malignant Tumors: Molecular Targets and Combinatorial Therapeutics)
    Abstract Breast cancer, a predominant global health issue, requires ongoing exploration of new therapeutic strategies. Palbociclib (PAL), a well-known cyclin-dependent kinase (CDK) inhibitor, plays a critical role in breast cancer treatment. While its efficacy is recognized, the interplay between PAL and cellular autophagy, particularly in the context of the RAF/MEK/ERK signaling pathway, remains insufficiently explored. This study investigates PAL’s inhibitory effects on breast cancer using both in vitro (MCF7 and MDA-MB-468 cells) and in vivo (tumor-bearing nude mice) models. Aimed at elucidating the impact of PAL on autophagic processes and exploring the potential of combining it with trametinib… More >

    Graphic Abstract

    Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition

  • Open AccessOpen Access

    ARTICLE

    ROR2 promotes invasion and chemoresistance of triple-negative breast cancer cells by activating PI3K/AKT/mTOR signaling

    XIA DA1, HAN GE2, JUNFENG SHI3, CHUNHUA ZHU1, GUOZHU WANG1, YUAN FANG4,*, JIN XU1,*
    Oncology Research, Vol.32, No.7, pp. 1209-1219, 2024, DOI:10.32604/or.2024.045433 - 20 June 2024
    (This article belongs to the Special Issue: Cancer Metastasis)
    Abstract Objective: This study aimed to investigate the role of receptor tyrosine kinase-like orphan receptor 2 (ROR2) in triple-negative breast cancer (TNBC). Methods: ROR2 expression in primary TNBC and metastatic TNBC tissues was analyzed by immunohistochemical staining and PCR. ROR2 expression in TNBC cell lines was detected by PCR and Western blot analysis. The migration, invasion and chemosensitivity of TNBC cells with overexpression or knockdown of ROR2 were examined. Results: ROR2 expression was high in metastatic TNBC tissues. ROR2 knockdown suppressed the migration, invasion and chemoresistance of TNBC cells. ROR2 overexpression in MDA-MB-435 cells promoted the migration, More >

  • Open AccessOpen Access

    ARTICLE

    LncRNA PCGEM1 facilitates cervical cancer progression via miR-642a-5p/KIF5B axis

    YUANLIN LIU1,3,#, YAN LIU2,#, YAN WANG2, QIANG WANG2, YAN YAN1, DANDAN ZHANG2,*, HUIQIN LIU2,*
    Oncology Research, Vol.32, No.7, pp. 1221-1229, 2024, DOI:10.32604/or.2024.047454 - 20 June 2024
    Abstract At present, the role of many long non-coding RNAs (lncRNAs) as tumor suppressors in the formation and development of cervical cancer (CC) has been studied. However, lncRNA prostate cancer gene expression marker 1 (PCGEM1), whose high expression not only aggravates ovarian cancer but also can induce tumorigenesis and endometrial cancer progression, has not been studied in CC. The objective of this study was to investigate the expression and the underlying role of PCGEM1 in CC. The relative expression of PCGEM1 in CC cells was detected by real-time PCR. After the suppression of PCGEM1 expression by… More >

    Graphic Abstract

    LncRNA PCGEM1 facilitates cervical cancer progression via miR-642a-5p/KIF5B axis

  • Open AccessOpen Access

    ARTICLE

    The effect of celastrol in combination with 5-fluorouracil on proliferation and apoptosis of gastric cancer cell lines

    MOHAMMAD-TAGHI MORADI1, DHIYA ALTEMEMY2, MAJID ASADI-SAMANI3,*, PEGAH KHOSRAVIAN1, MARZIYEH SOLTANI3, LEILA HASHEMI1, AZADEH SAMIEI-SEFAT3
    Oncology Research, Vol.32, No.7, pp. 1231-1237, 2024, DOI:10.32604/or.2024.047187 - 20 June 2024
    Abstract Background: Despite the availability of chemotherapy drugs such as 5-fluorouracil (5-FU), the treatment of some cancers such as gastric cancer remains challenging due to drug resistance and side effects. This study aimed to investigate the effect of celastrol in combination with the chemotherapy drug 5-FU on proliferation and induction of apoptosis in human gastric cancer cell lines (AGS and EPG85-257). Materials and Methods: In this in vitro study, AGS and EPG85-257 cells were treated with different concentrations of celastrol, 5-FU, and their combination. Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The synergistic effect… More >

Per Page:

Share Link